ATE207495T1 - Peptide des menschlichen papillomavirus zur verwendung in zusammensetzungen, die eine menschliche t-zellreaktion induzieren - Google Patents

Peptide des menschlichen papillomavirus zur verwendung in zusammensetzungen, die eine menschliche t-zellreaktion induzieren

Info

Publication number
ATE207495T1
ATE207495T1 AT93913618T AT93913618T ATE207495T1 AT E207495 T1 ATE207495 T1 AT E207495T1 AT 93913618 T AT93913618 T AT 93913618T AT 93913618 T AT93913618 T AT 93913618T AT E207495 T1 ATE207495 T1 AT E207495T1
Authority
AT
Austria
Prior art keywords
human
papilloma virus
induce
compositions
cell response
Prior art date
Application number
AT93913618T
Other languages
English (en)
Inventor
Wybe Martin Kast
Cornelis Joseph Maria Melief
Alessandro D Sette
John C Sidney
Original Assignee
Univ Leiden
Seed Capital Investments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Seed Capital Investments filed Critical Univ Leiden
Application granted granted Critical
Publication of ATE207495T1 publication Critical patent/ATE207495T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93913618T 1992-05-05 1993-05-04 Peptide des menschlichen papillomavirus zur verwendung in zusammensetzungen, die eine menschliche t-zellreaktion induzieren ATE207495T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP92201252 1992-05-05
EP92203870 1992-12-10
EP93200243 1993-02-01
EP93200621 1993-03-05
PCT/NL1993/000093 WO1993022338A1 (en) 1992-05-05 1993-05-04 Peptides of human papilloma virus for use in human t cell response inducing compositions

Publications (1)

Publication Number Publication Date
ATE207495T1 true ATE207495T1 (de) 2001-11-15

Family

ID=27442368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93913618T ATE207495T1 (de) 1992-05-05 1993-05-04 Peptide des menschlichen papillomavirus zur verwendung in zusammensetzungen, die eine menschliche t-zellreaktion induzieren

Country Status (15)

Country Link
US (1) US7364741B1 (de)
EP (1) EP0593754B1 (de)
JP (1) JP3609405B2 (de)
AT (1) ATE207495T1 (de)
AU (2) AU675794B2 (de)
CA (1) CA2112798A1 (de)
DE (1) DE69330988T2 (de)
DK (1) DK0593754T3 (de)
ES (1) ES2169043T3 (de)
FI (1) FI940054A0 (de)
IL (1) IL105554A (de)
NO (1) NO940043D0 (de)
NZ (1) NZ253330A (de)
PT (1) PT593754E (de)
WO (1) WO1993022338A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
CN1118572A (zh) * 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
US5480970A (en) * 1993-12-22 1996-01-02 Resolution Pharmaceuticals Metal chelators
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US20040002117A1 (en) 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
WO1999040930A1 (en) 1998-02-12 1999-08-19 Center For Blood Research, Inc. Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP2100620A1 (de) * 1999-09-16 2009-09-16 Eisai Corporation of North America Polyepitop-Polypeptide kodierende Nukleinsäuren
FR2794371B1 (fr) * 1999-10-07 2004-06-18 Biovector Therapeutics Fragments proteiquespolyepitopiques, leur obtention et leurs utilisations notamment en vaccination
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2002077012A2 (en) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
US7666391B2 (en) 2001-06-01 2010-02-23 Burnham Institute For Medical Research Breast homing peptides and methods of identifying same using aminopeptidase P
WO2002099379A2 (en) * 2001-06-01 2002-12-12 The Burnham Institute Breast homing peptides and methods of identifying same using aminopeptidase p
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8926961B2 (en) * 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
US8652482B2 (en) * 2007-10-03 2014-02-18 The Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
CA2721366C (en) 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation of an immune response by enantiomers of cationic lipids
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
CN102153656B (zh) * 2011-01-12 2014-11-19 广州市元通医药科技有限公司 一种嵌合病毒样颗粒疫苗及其制备方法
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3377099A4 (de) 2015-11-18 2019-07-24 ImmunoVaccine Technologies Inc. Adjuvante systeme und wasserfreie impfstoffzusammensetzung aus einem polyi:c-polynukleotidadjuvans und adjuvans auf lipidbasis
US12303561B2 (en) * 2017-04-03 2025-05-20 Biontech Us Inc. Protein antigens and uses thereof
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
CA3084957A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
WO2020132136A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
FR2641081A1 (de) 1988-12-23 1990-06-29 Medgenix Group
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
DE4015044A1 (de) * 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
CN1067382A (zh) 1990-09-26 1992-12-30 布里斯托尔-迈尔斯斯奎尔公司 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用
US6183745B1 (en) * 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5679509A (en) * 1993-09-28 1997-10-21 University Of New Mexico Methods and a diagnostic aid for distinguishing a subset of HPV that is associated with an increased risk of developing cervical dysplasia and cervical cancer
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) * 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6242176B1 (en) * 1998-07-13 2001-06-05 Loyola University Of Chicago Papillomavirus cellular receptor
US6548299B1 (en) * 1999-11-12 2003-04-15 Mark J. Pykett Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices
WO2000039188A1 (en) * 1998-12-25 2000-07-06 Mitsubishi Rayon Co., Ltd. Epoxy resin composition, prepreg, and roll made of resin reinforced with reinforcing fibers
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
DK1296711T3 (da) * 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus
DE10059631A1 (de) * 2000-12-01 2002-07-18 Medigene Ag T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie
WO2002077012A2 (en) * 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
EP1250005A1 (de) * 2001-04-12 2002-10-16 BRITISH TELECOMMUNICATIONS public limited company Videokommunikation mit Rückmeldung der relativen Position des Anrufenden zu der Kamera
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
EP1417353A4 (de) * 2001-07-20 2005-08-03 Univ Texas Verfahren und zusammensetzungen im zusammenhang mit hpv-assoziierten präkanzerösen und kanzerösen wucherungen, einschliesslich cin
US20040171081A1 (en) * 2001-11-23 2004-09-02 Abraham Mittelman Antigens
CA2500715A1 (en) * 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
CA2511775A1 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1,-a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
JP4647606B2 (ja) * 2003-09-05 2011-03-09 ジェネンコー・インターナショナル・インク Ｈｐｖｃｄ８＋ｔ細胞エピトープ
JP5030594B2 (ja) * 2003-12-23 2012-09-19 アルボー ビータ コーポレーション Ｈｐｖの発癌性株に対する抗体およびそれらの使用方法

Also Published As

Publication number Publication date
ES2169043T3 (es) 2002-07-01
CA2112798A1 (en) 1993-11-11
PT593754E (pt) 2002-04-29
DE69330988D1 (de) 2001-11-29
IL105554A (en) 1999-08-17
NZ253330A (en) 1996-06-25
AU675794B2 (en) 1997-02-20
FI940054A0 (fi) 1994-01-05
JPH07503975A (ja) 1995-04-27
NO940043D0 (no) 1994-01-05
EP0593754A1 (de) 1994-04-27
JP3609405B2 (ja) 2005-01-12
WO1993022338A1 (en) 1993-11-11
DK0593754T3 (da) 2002-02-18
AU7197096A (en) 1997-02-06
AU4358693A (en) 1993-11-29
US7364741B1 (en) 2008-04-29
EP0593754B1 (de) 2001-10-24
DE69330988T2 (de) 2002-06-20
IL105554A0 (en) 1993-08-18

Similar Documents

Publication Publication Date Title
ATE207495T1 (de) Peptide des menschlichen papillomavirus zur verwendung in zusammensetzungen, die eine menschliche t-zellreaktion induzieren
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
ATE326479T1 (de) Varianten von antigenen des menschlichen papillomvirus
ZA987591B (en) Vaccine.
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
DE60140794D1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
BR9814487A (pt) "vacina"
EP1319023B8 (de) Peptid aus hsp70 welches nk zellaktivität stimuliert und seine verwendung
CA2042236A1 (en) Seroreactive epitopes on proteins of human papillomavirus (hpv) 18
CA2424700A1 (en) Genetic immunisation against cervical carcinoma
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
WO1994026903A3 (en) Human influenza virus peptides binding hla-i molecule
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
ATE240349T1 (de) Peptide zur inhibierung von hpv e6-proteinen
Monroy-Garcı́a et al. Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection
AU4712993A (en) New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
WO2000006735A8 (en) Interferon alpha hybrids
JPS6455182A (en) Human papilloma virus of type 41, dna thereof and protein coded thereby
TR199802387T2 (xx) Do�um kontrol� i�in kullan�lan Zona Pellucida proteinleri.
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
AU2001263888A1 (en) Uses of tgap7 for the modulation of leucocyte activation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee